Opendata, web and dolomites


Molecular profiling of Bladder Cancer to support personalized medicine

Total Cost €


EC-Contrib. €






Project "BioMedBC" data sheet

The following table provides information about the project.


Organization address
postcode: 30659

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website
 Total cost 159˙460 €
 EC max contribution 159˙460 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2017
 Duration (year-month-day) from 2017-04-01   to  2019-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MOSAIQUES DIAGNOSTICS GMBH DE (HANNOVER) coordinator 159˙460.00


 Project objective

BioMedBC Proposal is focused on improving the patient management of Bladder Cancer (BC). BC presents with the highest recurrence rate and the highest associated costs of all cancers. Due to the intrinsic heterogeneity, the investigated drugs in clinical trials, cannot be easily introduced in the clinical practice. Molecular profiles/ biomarkers (BM) with predictive potential are required to enable patient stratification. The BioMedBC proposal aims at the application of systems biology and cross-omics data integration methodologies to achieve: a) the molecular characterization of BC and b) develop signatures to predict the clinical outcome. To achieve these goals, integration of: i) high resolution proteomics datasets (planned to be acquired within BioMedBC), ii) existing datasets that were obtained in previous EU collaborative projects and iii) publicly available transcriptomics data, will be conducted, focusing on the molecular characterization of BC. Emphasis is given on the investigation of disease prognosis. For this purpose, clinical and follow-up data, available from ongoing prospective studies (n=1758), will be utilized for correlation analysis of the molecular profiles/ biomarkers with disease outcome (recurrence, progression and survival). The prognostic value will be confirmed in newly collected samples with emphasis placed on urinary protein/ peptide profiles, as non-invasive urinary markers is of significant added value. The innovation is held on the prognostic BM that can be further used to stratify patients to those that could be benefited by a potential intervention and guide personalized therapy to improve BC patient management. In parallel, BioMedBC aims at expanding upon the current training of the ER, Dr. Maria Frantzi, on transferability of the basic research results to clinically useful products and create strong career prospects for her desired development as an owner of a future SME.


year authors and title journal last update
List of publications.
2019 Magdalena Krochmal, Kim E. M. van Kessel, Ellen C. Zwarthoff, Iwona Belczacka, Martin Pejchinovski, Antonia Vlahou, Harald Mischak, Maria Frantzi
Urinary peptide panel for prognostic assessment of bladder cancer relapse
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-019-44129-y
Scientific Reports 9/1 2019-09-30
2018 Agnieszka Latosinska, Maria Frantzi, Axel S. Merseburger, Harald Mischak
Promise and Implementation of Proteomic Prostate Cancer Biomarkers
published pages: 57, ISSN: 2075-4418, DOI: 10.3390/diagnostics8030057
Diagnostics 8/3 2019-09-30
2018 Agnieszka Latosinska, Maria Frantzi, Antonia Vlahou, Axel S. Merseburger, Harald Mischak
Clinical Proteomics for Precision Medicine: The Bladder Cancer Case
published pages: 1700074, ISSN: 1862-8346, DOI: 10.1002/prca.201700074
PROTEOMICS - Clinical Applications 12/2 2019-09-30
2018 Maria Frantzi, Agnieszka Latosinska, Georgia Kontostathi, Harald Mischak
Clinical Proteomics: Closing the Gap from Discovery to Implementation
published pages: 1700463, ISSN: 1615-9853, DOI: 10.1002/pmic.201700463
PROTEOMICS 18/14 2019-09-30
2017 Iwona Belczacka, Agnieszka Latosinska, Jochen Metzger, David Marx, Antonia Vlahou, Harald Mischak, Maria Frantzi
Proteomics biomarkers for solid tumors: Current status and future prospects
published pages: 49-78, ISSN: 0277-7037, DOI: 10.1002/mas.21572
Mass Spectrometry Reviews 38/1 2019-09-30
2019 Maria Frantzi, Harald Mischak, Agnieszka Latosinska
Clinical Proteomics on the Path Toward Implementation: First Promises Delivered
published pages: 1800094, ISSN: 1862-8346, DOI: 10.1002/prca.201800094
PROTEOMICS – Clinical Applications 13/2 2019-09-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOMEDBC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOMEDBC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

MathematicsAnalogies (2019)

Mathematics Analogies

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More